A Phase 1 Study of MKC-1 in Patients With Refractory Hematologic Malignancies
The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies
Hematological Malignancies|Myelodysplasia|Agnogenic Myeloid Metaplasia
DRUG: MKC-1
Occurrence of treatment emergent adverse events, Throughout study treatment
The main objectives of this study are to evaluate the side effects of MKC-1 and to determine a safe dose of MKC-1 for future studies in patients with hematological malignancies